Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma

Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma

Abstract Background Chemotherapeutic options for the treatment of canine lymphoma have not changed in several decades necessitating the identification of new therapeutics to improve patient outcome. KPT-335 (verdinexor) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) that...

Full description

Bibliographic Details
Main Authors: Abbey R. Sadowski, Heather L. Gardner, Antonella Borgatti, Heather Wilson, David M. Vail, Joshua Lachowicz, Christina Manley, Avenelle Turner, Mary K. Klein, Angharad Waite, Alexandra Sahora, Cheryl A. London
Format: Article
Language:English
Published: BMC 2018-08-01
Series:BMC Veterinary Research
Subjects:
Non-Hodgkin lymphoma
Nuclear export
Clinical trial
Anti-tumor agent
Online Access:http://link.springer.com/article/10.1186/s12917-018-1587-9

Internet

http://link.springer.com/article/10.1186/s12917-018-1587-9

Similar Items